Angiogenesis and tissue repair.
Promoting new blood-vessel formation, cell migration, and repair signalling.
Wound healing proceeds through overlapping phases: haemostasis, inflammation, proliferation, and remodelling. Angiogenesis, the growth of new capillaries from existing vessels, is essential to the proliferative phase because new tissue cannot be built or sustained without perfusion. It is driven largely by vascular endothelial growth factor acting on VEGFR2 on endothelial cells, with nitric oxide serving as a downstream and permissive signal that governs vessel dilation, endothelial survival, and sprouting. Cell migration is the other requirement: keratinocytes, fibroblasts, and endothelial cells must physically move into the wound bed, which depends on rapid reorganisation of the actin cytoskeleton. Compounds grouped here engage different points in that sequence. One acts most consistently through the nitric oxide system, promoting endothelial nitric oxide production, with protective effects that are blunted when nitric oxide synthase is blocked. It has been reported to activate a signalling chain involving Src, caveolin-1, and endothelial nitric oxide synthase, and to enhance VEGFR2-driven signalling, which is the proposed basis for its pro-angiogenic effects. It also has reported effects on gut mucosal protection and on tendon fibroblast behaviour. Others derive from a naturally occurring intracellular protein whose best-characterised function is binding monomeric actin in a one-to-one complex. By buffering the pool of unpolymerised actin, it modulates cytoskeletal assembly and therefore cell shape and motility. A short conserved motif within the protein has been reported to promote keratinocyte and endothelial migration, angiogenesis, and anti-inflammatory and anti-apoptotic effects in preclinical models. The relationship between the full protein and the fragment sold under a separate name is a frequent source of confusion, since they are related but not identical entities. This is a pathway where the gap between mechanism and proof is unusually wide, and it deserves plain statement. The molecular actions above are documented, but overwhelmingly in cell culture and rodent models of injury. Controlled human trials are sparse to absent for these compounds, none is an approved medicine for tissue repair in major jurisdictions, and material sold under these names is unregulated with uncertain identity and purity. Promoting angiogenesis is also not universally desirable, since the same signals that build capillaries into healing tissue could in principle support other proliferating tissue, and that question has not been addressed in humans.
Peptides acting through this pathway.
FAQ.
What does angiogenesis and tissue repair do?
Wound healing proceeds through overlapping phases: haemostasis, inflammation, proliferation, and remodelling. Angiogenesis, the growth of new capillaries from existing vessels, is essential to the proliferative phase because new tissue cannot be built or sustained without perfusion. It is driven largely by vascular endothelial growth factor acting on VEGFR2 on endothelial cells, with nitric oxide serving as a downstream and permissive signal that governs vessel dilation, endothelial survival, and sprouting. Cell migration is the other requirement: keratinocytes, fibroblasts, and endothelial cells must physically move into the wound bed, which depends on rapid reorganisation of the actin cytoskeleton. Compounds grouped here engage different points in that sequence. One acts most consistently through the nitric oxide system, promoting endothelial nitric oxide production, with protective effects that are blunted when nitric oxide synthase is blocked. It has been reported to activate a signalling chain involving Src, caveolin-1, and endothelial nitric oxide synthase, and to enhance VEGFR2-driven signalling, which is the proposed basis for its pro-angiogenic effects. It also has reported effects on gut mucosal protection and on tendon fibroblast behaviour. Others derive from a naturally occurring intracellular protein whose best-characterised function is binding monomeric actin in a one-to-one complex. By buffering the pool of unpolymerised actin, it modulates cytoskeletal assembly and therefore cell shape and motility. A short conserved motif within the protein has been reported to promote keratinocyte and endothelial migration, angiogenesis, and anti-inflammatory and anti-apoptotic effects in preclinical models. The relationship between the full protein and the fragment sold under a separate name is a frequent source of confusion, since they are related but not identical entities. This is a pathway where the gap between mechanism and proof is unusually wide, and it deserves plain statement. The molecular actions above are documented, but overwhelmingly in cell culture and rodent models of injury. Controlled human trials are sparse to absent for these compounds, none is an approved medicine for tissue repair in major jurisdictions, and material sold under these names is unregulated with uncertain identity and purity. Promoting angiogenesis is also not universally desirable, since the same signals that build capillaries into healing tissue could in principle support other proliferating tissue, and that question has not been addressed in humans.
Which peptides act through angiogenesis and tissue repair?
BPC-157, TB-500, Thymosin β-4. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.